부산대학교 도서관

A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes...nsulin degludec as basal-bolus therapy (study B): Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muńoz-Torres M, Rosenstock J, Endahl LA, Ocampo Francisco AM, Hollander P, on behalf of the NN1250-3582 (BEGIN Basal-Bolus Type 2) Trial Investigators: Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes: a phase 3, randomized, open-label, treat-to-target noninferiority trial. Lancet 379:1498–1507, 2012.